...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy
【24h】

Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy

机译：诺华单抗难治性肺癌对挽救性化疗的显着反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Promising outcomes of salvage chemotherapy after nivolumab therapy have been reported; however, little is known about the detailed clinical and immunologic features in lung cancer patients in whom nivolumab is unsuccessful. We report two cases of nivolumab-refractory lung cancer, in which chemotherapy resulted in rapid regression of the lung cancer. Upon initial diagnosis, the biopsy specimens showed PD-ligand 1 (PD-L1)-expressing cancer cells, accompanied by tumor-infiltrating lymphocytes with a favorable CD8/CD4 ratio. Immunosuppressive regulatory T cells and cells positive for TIM-3 were also observed. Physicians should take caution in treating lung cancer patients after progression on nivolumab. Further studies with a large cohort are warranted to identify the patients that may benefit from salvage chemotherapy.
机译：摘要有报道称尼古鲁单抗治疗后挽救性化疗的前景看好。然而，对于nivolumab治疗失败的肺癌患者的详细临床和免疫学特征知之甚少。我们报告了两例纳武单抗难治性肺癌，其中化学疗法导致了肺癌的快速消退。初步诊断后，活检标本显示表达PD-配体1（PD-L1）的癌细胞，并伴有CD8 / CD4比值良好的肿瘤浸润淋巴细胞。还观察到免疫抑制性调节性T细胞和TIM-3阳性细胞。在使用nivolumab治疗后，医师应谨慎对待肺癌患者。有必要对大量患者进行进一步研究，以鉴定可能从挽救性化疗中受益的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号